CA-170

CA-170 is an investigational new drug being evaluated as an immune checkpoint inhibitor for the treatment of cancer. Developed by Aurigene Oncology, it is an orally available small molecule designed to selectively inhibit the immune checkpoint proteins PD-L1^[1] and VISTA,^[2] both of which are key negative regulators of T-cell activation implicated in cancer immune evasion.^[3][4]

CA-170

Identifiers
IUPAC name (2S,3R)-2-[[(1S)-3-amino-1-[3-[(1R)-1-amino-2-hydroxyethyl]-1,2,4-oxadiazol-5-yl]-3-oxopropyl]carbamoylamino]-3-hydroxybutanoic acid
CAS Number	1673534-76-3
PubChem CID	126843231
DrugBank	DB15772
ChemSpider	68025713
UNII	646MN6KQ16
ChEMBL	ChEMBL5411171
Chemical and physical data
Formula	C12H20N6O7
Molar mass	360.327 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@H]([C@@H](C(=O)O)NC(=O)N[C@@H](CC(=O)N)C1=NC(=NO1)[C@H](CO)N)O
InChI InChI=1S/C12H20N6O7/c1-4(20)8(11(22)23)16-12(24)15-6(2-7(14)21)10-17-9(18-25-10)5(13)3-19/h4-6,8,19-20H,2-3,13H2,1H3,(H2,14,21)(H,22,23)(H2,15,16,24)/t4-,5+,6+,8+/m1/s1 Key:HFOBENSCBRZVSP-LKXGYXEUSA-N

By targeting these immune pathways, CA-170 aims to restore and enhance the immune system’s ability to recognize and eliminate tumor cells, offering the potential for improved anti-tumor responses across a variety of cancers.^[4][5]